Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Emerging therapeutic targets for patients with advanced prostate cancer.

Publication ,  Journal Article
Saad, F; Shore, N; Zhang, T; Sharma, S; Cho, HK; Jacobs, IA
Published in: Cancer Treat Rev
June 2019

Although recent advances in the treatment of castration-resistant prostate cancer (CRPC) have significantly improved patient outcomes, advanced prostate cancer is still associated with substantial morbidity and mortality, particularly in patients who develop resistance after multiple lines of therapy. Various cell signaling, DNA repair, and epigenetic enzymatic pathways are being targeted with small-molecule inhibitors in order to identify treatment strategies for patients with CRPC. In this review, we discuss novel targets and agents, studied preclinically and now being validated in clinical trials, including poly ADP-ribose polymerase (PARP), enhancer of zeste homologue 2 (EZH2), hedgehog pathway, MDM2/p53, and tyrosine kinase inhibitors. Further, we outline current approaches for novel prostate cancer vaccines such as DCVAC/PCa, PROSTVAC-V/F, MVI-816, CV9104, and PF-06753512. This wide spectrum of potential treatment strategies holds promise for additional improvements in the treatment of patients with CRPC, as these novel agents are aimed at targets known to be associated with growth and malignant progression of prostate cancer. If primary study endpoints are met, findings from ongoing phase III trials of well-tolerated and active combinations may provide new effective treatment options for advanced prostate cancer and thereby contribute to enhanced disease control in CRPC patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Treat Rev

DOI

EISSN

1532-1967

Publication Date

June 2019

Volume

76

Start / End Page

1 / 9

Location

Netherlands

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Prostatic Neoplasms, Castration-Resistant
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Male
  • Humans
  • Cancer Vaccines
  • Animals
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Saad, F., Shore, N., Zhang, T., Sharma, S., Cho, H. K., & Jacobs, I. A. (2019). Emerging therapeutic targets for patients with advanced prostate cancer. Cancer Treat Rev, 76, 1–9. https://doi.org/10.1016/j.ctrv.2019.03.002
Saad, Fred, Neal Shore, Tian Zhang, Shikhar Sharma, Helen K. Cho, and Ira A. Jacobs. “Emerging therapeutic targets for patients with advanced prostate cancer.Cancer Treat Rev 76 (June 2019): 1–9. https://doi.org/10.1016/j.ctrv.2019.03.002.
Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA. Emerging therapeutic targets for patients with advanced prostate cancer. Cancer Treat Rev. 2019 Jun;76:1–9.
Saad, Fred, et al. “Emerging therapeutic targets for patients with advanced prostate cancer.Cancer Treat Rev, vol. 76, June 2019, pp. 1–9. Pubmed, doi:10.1016/j.ctrv.2019.03.002.
Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA. Emerging therapeutic targets for patients with advanced prostate cancer. Cancer Treat Rev. 2019 Jun;76:1–9.
Journal cover image

Published In

Cancer Treat Rev

DOI

EISSN

1532-1967

Publication Date

June 2019

Volume

76

Start / End Page

1 / 9

Location

Netherlands

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Prostatic Neoplasms, Castration-Resistant
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Male
  • Humans
  • Cancer Vaccines
  • Animals
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis